Raymond James Financial
CRMD icon

Raymond James Financial’s CorMedix CRMD Stock Holding History

Raymond James Financial’s Portfolio CRMD Stock Details CRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.23M Sell
328,224
-137,217
-29% -$1.01M ﹤0.01% 3273
2025
Q4 		$5.41M Sell
465,441
-186,546
-29% -$2.06M ﹤0.01% 2448
2025
Q3 		$7.58M Buy
651,987
+564,688
+647% +$6.83M ﹤0.01% 2142
2025
Q2 		$1.08M Sell
87,299
-53,456
-38% -$590K ﹤0.01% 3532
2025
Q1 		$867K Buy
140,755
+25,094
+22% +$260K ﹤0.01% 3592
2024
Q4 		$937K Buy
+115,661
New +$1.16M ﹤0.01% 3493

Other funds holding CRMD

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
OAM
Oberweis Asset Management Lisle, Illinois $3.39B AUM 105.5% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Raymond James Financial's CRMD Position: Q1 2026 in Review

Raymond James Financial reduced its CorMedix (CRMD) stake by 29% in Q1 2026, selling an estimated $1.01M and leaving 328,224 shares worth $2.23M. The position accounts for ﹤0.01% of the portfolio, ranked #3273.

Raymond James Financial first reported a position in CRMD in Q4 2024 and has held it in 6 quarters since. The position peaked at $7.58M in Q3 2025. 187 funds tracked by Wall St. Rank hold CRMD as of Q1 2026.

  • Raymond James Financial held 328,224 shares of CorMedix worth $2.23M as of Q1 2026.
  • Raymond James Financial sold 137,217 CorMedix shares in Q1 2026, an estimated $1.01M.
  • CorMedix made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #3273 holding.
  • Raymond James Financial first reported a position in CorMedix in Q4 2024 and has held it in 6 quarters since.
  • Raymond James Financial's CorMedix position peaked at $7.58M in Q3 2025.
  • 187 funds tracked by Wall St. Rank held CorMedix as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.